From £6.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £6.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Latest Views & News

GlaxoSmithKline – Q1 update, still further share price upside as demerger nears

By Tom Winnifrith and Steve Moore | Monday 2 May 2022


Disclosure: I own shares in one or more of the stocks mentioned. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


GlaxoSmithKline (GSK) has announced its first quarter of the year results and that it reconfirms its full-year 2022 guidance. We are well ahead on this share tip where we are also drinking our own medicine so what to do now?

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

ICON

Iconic Labs – its alive!

Wednesday »

Bearcast

Tom Winnifrith Bearcast: Family tales

 

SHG

Shanta Gold – a recovery BUY!

 

MUSH

Oscillate RTO – madness

 

MOON

Surely Moonpig is a short at 171p?

 

Atomic

Video: The Road to an Energy Crisis

 

Bear

Beyond Meat is Beyond Redemption.

Friday »

Bearcast

Tom Winnifrith bearcast: Madness!

 

RRR

The Andrew Bell defence at Red Rock